Ranbaxy, Glaxo Bury Hatchet Over Valtrex

Law360, New York (July 26, 2007, 12:00 AM EDT) -- In a boost to Ranbaxy Laboratories Ltd., the Indian drug giant has won 180 days of exclusive rights to sell a generic version of GlaxoSmithKline's Valtrex in the United States after the two rivals settled a long-running patent dispute over the herpes treatment.

Ranbaxy said Thursday it had reached an agreement with Glaxo that had resulted in a dismissal of their U.S. litigation over Glaxo's U.S. Patent Number 4,957,924, which covers valacyclovir hydrochloride. In early February, Ranbaxy received a final approval from the U.S. Food and...
To view the full article, register now.